Pfizer Expects that Six Rare Disease Therapies will Enter Phase III Trials

Pfizer has a huge research and development channel for vaccines, and its annual sales are expected to exceed $15 billion by 2025. The company’s upcoming spin-off of Upjohn’s investment portfolio will free it from unnecessary burdens and help it become an innovation-driven biopharmaceutical company. The company’s revenue is expected to grow at an annual rate of 6%, while achieving double-digit profit growth.

In terms of rare diseases, Pfizer expects that six rare disease therapies will enter Phase III trials by the end of this year, including three gene therapies. The company has also developed a series of immune products, each corresponding to a variety of symptoms, and has the potential to become the final product. The main responsible unit of this business unit is abroctinib, an oral JAK inhibitor, which was applied by Pfizer last month for the treatment of atopic dermatitis. Pfizer believes that the annual sales of this therapy may exceed $3 billion.

Pfizer also plans to launch six new vaccines by 2025. In the cooperation between the company and BioNTech (BNTX.US) on the COVID-19 vaccine, Divan expressed that he is encouraged by the data so far, and believes that Pfizer can have a clear understanding of the vaccine profile by the end of October, and obtain it in the near future. Approved by the U.S. Food and Drug Administration.

The analyst believes that the risk-adjusted vaccine sales will reach approximately US$1.7 billion next year and US$1.2 billion in 2022.

Editor’s note: This article is for reference only and does not constitute an offer, or invitation, inducement, any representation regardless of type or form, or make any suggestions and recommendations. Readers should use their independent thinking ability to make their own investment decisions If any losses are incurred due to the relevant recommendations, it has nothing to do with , the editor and the author.


Reviewer overview

Pfizer Expects that Six Rare Disease Therapies will Enter Phase III Trials - /10


0 Bad!